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Neuroendocrine tumor (NET) patients must be adequately staged in order to improve a multidisciplinary
approach and optimal management for metastatic disease. Currently available imaging studies include
somatostatin receptor scintigraphy, like OctreoScanW, computed tomography (CT), scans and magnetic resonance
imaging (MRI), which analyze vascular concentration and intravenous contrast enhancement for anatomic tumor
localization. However, these techniques require high degree of expertise for interpretation and are limited by
their availability, cost, reproducibility, and follow-up imaging comparisons. NETs significantly reduce water
diffusion as compared to normal tissue. Diffusion-weighted imaging (DWI) in MRI has an advantageous contrast
difference: the tumor is represented with high signal over a black normal surrounding background. The whole-
body diffusion (WBD) technique has been suggested to be a useful test for detecting metastasis from various
anatomic sites. In this article we report the use of DWI in MRI and WBD in two cases of metastatic pulmonary
NET staging in comparison with OctreoScanW in order to illustrate the potential advantage of DWI and WBD in
staging NETs.
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Neuroendocrine tumors (NETs) are heterogeneous ma-
lignant neoplasms that originate from neuroendocrine
cells located in various anatomic sites of the body. They
are classically associated with symptoms resulting from
secretion of hormones or vasoactive peptides into the
systemic circulation, and classified as functioning and
non-functioning tumors. The Surveillance, Epidemiology,
and End Results Program database reported the incidence
of 5.25 cases per 100,000 for the 2004 United States
population [1]. The long survival experienced by NET
patients explains its high prevalence, which was estimated
in 35/100,000 in the same population. Approximately
50 % of NET patients are diagnosed with localized disease
and surgical resection alone is often curative.
The liver is a frequent site of metastasis, with substan-
tial influence on prognosis [2–5]. Patients who present* Correspondence: fredericoperegocosta@gmail.com
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reproduction in any medium, provided the orwith advanced disease limited to the liver may also bene-
fit from surgical resection with potential curative intent
or to control hormone secretion refractory to biotherapy
or other systemic treatment options. In order to better
select candidates for surgical procedure, clinical staging
is fundamental.
Despite great technological improvement in imaging
acquisition in recent years, detection of hepatic lesions less
than 5 mm in diameter is still limited. Therefore, dif-
fusion-weighted imaging (DWI) in MRI has recently
emerged as a tool for detecting metastasis in the liver with-
out the need of i.v. contrast or radiation exposure [6,7].
DWI sequence can be adjusted to obtain images from the
entire body in one single acquisition called whole-body dif-
fusion imaging (WBD). To our knowledge, only limited
studies have addressed the value and the practicality of
MRI diffusion in staging NETs [8,9]. The objective of this
report is to assess the DWI and WBD in two patients with
metastatic neuroendocrine carcinoma and demonstrate its
potential use in comparison with OctreoScanW, commonly
used in the clinical staging of NET.l Ltd This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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We report two patients with metastaic neuroendocrine
carcinoma submitted to MRI with DWI and WBD and
OctreoScanW in their clinical staging. The imaging pro-
tocols and medical history is presented bellow.
MRI image protocol
MRI was performed with a 1.5-T whole-body imager
(Signa HDx; General Electric Medical Systems, Milwau-
kee, WI, USA). For every scan, whole-body examination
was obtained in axial and coronal plane using body coil.
Three sequences were obtained and the image para-
meters are described in the Table 1.
For each sequence, at least five continuous stations
covering the whole body from the top of the head to feet
were acquired. Estimated examination time is up to
30 min.
The diffusion encoding was done in only one direction
and the lesions detected in the diffusion-weighted se-
quence were analyzed in terms of number, size, location,
and signal intensity. These lesions were compared to the
T1-weighted and STIR (Short TI Inversion Recovery)
sequences to rule out benign lesions (false-positive).
Using quantitative analysis, an apparent diffusion coeffi-
cient map (ADC map) was calculated for the main lesions
in each patient. After these analyses, all lesions consid-
ered malignant were correlated with OctreoScanW with
time interval between the exams of less than one week.
Somatostatin receptor scintigraphy
Somatostatin receptor scintigraphy (SRS) is a functional
technique for the imaging of NETs. There is a variety ofTable 1 Whole-body magnetic scan parameters: all
images were obtained using a body coil and with
free-breathing technique
Parameter DWI T1 STIR
TR/TE 6750/64 1000/4.6 3200/60
Inversion time (ms) 180 - 180
Field of view (mm) 450 450 450







Signals averaged (n) 6 1 2
Blocks (n) 5 5 5




1 min 40s for
each block
B-value (s/mm2) 0, 600 - -
Bandwidth (kHz) 125 62.5 50
Dash (-) indicates not applicable.
DWI, diffusion-weighted imaging; STIR, Short T1 Inversion Recovery.peptides (known as somatostatin analogues) which target
these receptors, and which differ in their ability to bind
to the various receptor subtypes (SSTR). The most com-
monly used somatostatin analogue is octreotide which is
labeled with 111In, using the chelator diethylenetria-
mine-pentaaceticacid (DTPA), to produce 111In-DTPA-
octreotide [6–11] which is available as a commercial
product (OctreoScanW-Mallinckrodt, Inc.). OctreoScanW
was supplied as two vials: Vial A - 111In as InCl3,
122 MBq (3.3 mCi)/1.1 ml; Vial B - 10 μg of lyophilized
pentetreotide and excipients. The maximum amount of
IV pentetreotide injected is 10 μg.
OctreoScanW images are obtained by using a gamma
camera fitted with a medium-energy, parallel hole colli-
mator (Symbia T2, Siemens) with hybrid technique
SPECT/CT (single-photon emission computed tomog-
raphy and digital computed tomography at the same
study). Planar and SPECT images were acquired at 4
and 24 h post-injection.
Medical history
Patient 1
A 31-year-old female underwent dermatological evalu-
ation for resection of a subcutaneous nodule. Patho-
logical analysis demonstrated an adenocarcinoma with
positive margins. The patient underwent wide excision
of surgical margins and pathology revealed a NET with
positive staining for chromogranin A and neuron-
specific enolase. A chest CT scan showed a pulmonary
mass in the left lobar bronchia. The patient underwent
left pneumectomy. Pathology confirmed a 4.5-cm well-
differentiated neuroendocrine carcinoma, with a low
mitotic count of 1 mitosis per 10 HPF (high power
field). There was no vascular or pleural invasion and
surgical margins were free. One lymph node was
involved. A staging abdominal ultrasound revealed the
presence of two hepatic nodules in segment VIII,
measuring 1.8 and 1.0 cm. An abdominal MRI showed
multiple hepatic nodules, with additional lesions in
segments II and V. Octreoscan showed increased activ-
ity on pulmonary and hepatic tumoral lesions. Labora-
tory screening was unremarkable. The patient was
treated with somatostatin analogs. Follow-up abdom-
inal MRI revealed multiple new hepatic and bone
lesions. In the WBD images, a new small sacral lesion
was detected in correlation with a low signal nodule
on the T1-weighted images and therefore raised sus-
picion for metastasis (Figure 1A and 1 C). The
OctreoscanW performed in the same week of the
WBD/MRI showed focal uptake in this area (Figure 1B)
confirming that WBI added valuable information for
staging. Everolimus was added to the treatment regi-
men. Follow-up images revealed stable disease after
three months.
A B C
Figure 1 Comparison of DWI (A), 111 In-pentetreotide scintigraphy images (B) and T1-weighted (C) showing bone metastasis in left
sacral bone detected by diffusion-weighted imaging (blue arrow) and confirmed by T1 sequence (green arrow). The hyperintense signal
in the right subcutaneous fluid (yellow arrow) is a pitfall due to T2 shine-throught effect and should not be interpreted as metastasis.
OctreoScanW image (B) reveals correlation between radiotracer uptake (red arrow) and MR findings.
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A 23-year-old male presented with sporadic haemoptysis
over the last year. A CT scan of the thorax showed an
intra-bronchial lesion with 3.0 × 2.3 cm in the right in-
ferior lobar bronchia and a bronchoscopy confirmed a
well-differentiated NET, grade 1. The tumor was a non-
functioning pulmonary NET-1. He underwent a right in-
ferior lobectomy. Pathology reported an invasive well-
differentiated pulmonary neuroendocrine tumor, grade
1, measuring 2.2 cm, with predominant endobronchial
growth, with less than 1 mitosis per 10 HPF. There was
neither neural-vascular invasion nor necrosis. According
to pathological analysis, zero of two mediastinal lymph
nodes were affected (pT1b pN0). Immunohistochemistry
revealed a proliferation index (Ki67) of< 1 %, with posi-
tive staining for chromogranin A, synaptophysin, cyto-
keratin(CK)-40, CK-48, CK-50,6 and kDa, and negative
staining for TTF-1. A staging CT scan of thorax, abdo-
men, and pelvis demonstrated unexpected small round
hypointense lesions distributed throughout the liver par-
enchyma, seen only on the venous phase, measuring less
than 10 mm. Laboratory exams were relevant for serum
chromogranin A 38 ng/mL (normal reference value: <
15 ng/mL) and urinary 5-hydroxyindoleacetic acid (5-
HIAA) 5.7 mg/24 h (normal reference value: < 8.2 mg/
24 h). The patient was referred for hepatic resection at
our center. An abdominal MRI was performed to evalu-
ate the hepatic lesions, revealing multiple hypervascular
nodules scattered throughout the liver with washout on
the delayed phase. All these hepatic lesions were
detected in the DW images. WBD images revealed, in
addition to the hepatic lesions, mediastinal lymph nodes
with restricted diffusion confirmed in the ADC maps
raising suspicion for metastatic lesions (Figure 2A). TheOctreoscanW performed on the day after showed focal
areas of uptake in superior mediastinal, para-tracheal,
subcarinal and right pulmonar hilar lymph nodes and
hepatic nodules in segments V/VIII and III (Figure 2B).
The patient was submitted to a fine needle aspiration bi-
opsy of the large hepatic lesion, which confirmed meta-
static neuroendocrine carcinoma. Treatment with
somatostatin analogs was initated.
Discussion
Magnetic resonance or computed tomography (CT) ex-
plore NET characteristics of being highly vascular and
enhance intensely with intravenous contrast during the
early arterial phases with washout in the delayed phases.
On the other hand, liver metastasis may appear isodense
in pre-contrast and venous phases causing poor
visualization. This variation creates challenges in staging
and evaluating tumor response or progression during
treatment. Multiphase CT, which includes both arterial
and portal venous phase images, is often used to stage
and access tumor response in patients with NET. Mag-
netic resonance imaging (MRI) is also a commonly used
alternative for imaging NET. Metastatic lesions can be
visualized with and without gadolinium contrast, espe-
cially in T2-weighted sequences, reducing the variability
sometimes seen with CT-based imaging results [10,11].
However, both imaging methods require intravenous
(i.v.) contrast.
Scintigraphic technique is also commonly used to
stage NET by identifying primary and metastatic ana-
tomic sites, especially in well and moderately-differen-
tiated NETs. OctreoScanW specifically binds to SSTR,
with particular affinity for subtypes 2, 3, and 5, when
they are expressed in tumor. 68 Ga-DOTANOC is
A B C
Figure 2 Comparison of DWI (A) and 111 In-pentetreotide scintigraphy (B) images reveal correlation between hyperintense
mediastinal lymph nodes (blue arrows) and radiotracer uptake (red arrow). All the metastatic liver lesions detected by scintigraphy (yellow
arrows) appeared as hyperintense nodules in the DWI (green arrows). T1-weighted image (C) shows the potential application of this method to
detect bone metastasis (purple arrows).
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finity with SSTR. It seems to provide better visualization
and relevant information in the management of NET
patients compared to OctreoScanW, although this new
peptide is still not widely available outside a small num-
ber of referring centers in the world [12–14].
NETs significantly reduce water diffusion compared to
normal tissues. DWI in MRI has an advantageous con-
trast difference for lesion detection: the tumor is repre-
sented with high signal over a black normal surrounding
tissue. This is a patient-friendly tool that does not re-
quire i.v. contrast, does not use ionizing radiation, and
can be correlated with other T1/T2 MRI acquisitions for
better tumor location and characterization. The WBD
image is a fast acquisition phase and can be easily used
as a roadmap to identify small and large NET lesions.
Repeated images can also be made in order to assess
tumor response, not only with morphological analysis
but also providing functional information through quan-
tification of apparent diffusion coefficient (ADC) values.
The precise anatomic information, the speed of imaging
acquisition, the lack of endovenous contrast, wide avail-
ability, and low cost make the whole body diffusion areliable and attractive staging method that should be fur-
ther investigated.
WBD has been shown to be the most accurate tech-
nique for detecting metastasis of melanoma in the liver,
bone, subcutaneous tissue, and intra-peritoneum [15].
WBD has also been used to detect metastatic lesions
from paraganglioma and pheochromocytoma, with
higher rates of detection than 2-[(18)F]-fluoro-2-deoxy-
D-glucose positron emission tomography (FDG-PET) or
(123)I-meta-iodo-benzyl guanidine scintigraphy (MIBG)
[16].
Despite the paucity of diffusion MRI reports in NETs,
these two cases illustrate a potential role of DWI and
WBD as a cost-effective and less invasive method for
assessing NETs. Variations in water diffusion restriction
could provide information about tumor response during
treatment, with less cost and risks in comparison with
other standard methods. We acknowledge that the func-
tional information provided by WBD still needs further
evaluation and currently does not substitute OctreoS-
canW. A formal evaluation in NET patients should be
conduct to define the sensitivity and specificity of this
method in comparison with other standard imaging
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import role for staging NET in surgical candidates and
for following up patients on systemic therapy.Consent
Written informed consent was obtained from the
patients for publication of this case report and any ac-
companying images. A copy of the written consent is
available for review by the Editor-in-Chief of this
journal.
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